NIA | Jotup

Hudson Significantly Expands Duty Paid & Duty Free Operations At Boston Logan Int’l Airport

Retrieved on:

Tuesday, May 2, 2023

Now, under a 3-year extension for its duty paid business and a newly awarded 12-year contract for duty free, Hudson will expand its footprint in BOS even further – introducing a locally-inspired, globally-relevant concessions portfolio consisting of eight new duty paid and eight duty free stores in 2023 and 2024.

Key Points:

Now, under a 3-year extension for its duty paid business and a newly awarded 12-year contract for duty free, Hudson will expand its footprint in BOS even further – introducing a locally-inspired, globally-relevant concessions portfolio consisting of eight new duty paid and eight duty free stores in 2023 and 2024.
Terminals A, B, and C will have a duty free store where both domestic and international travelers can shop.
Terminal E, which is only for international travelers, will offer five distinctive duty free shops including an immersive, 11,000-square-foot walk-through store.
In the B/C Connector, Hudson will introduce a combination Hudson and Dunkin’ concept, and in Terminal E, Hudson will open a hybrid Hudson and F&B marketplace.

Hudson Significantly Expands Duty Paid & Duty Free Operations At Boston Logan Int’l Airport

Retrieved on:

Tuesday, May 2, 2023

Now, under a 3-year extension for its duty paid business and a newly awarded 12-year contract for duty free, Hudson will expand its footprint in BOS even further – introducing a locally-inspired, globally-relevant concessions portfolio consisting of eight new duty paid and eight duty free stores in 2023 and 2024.

Key Points:

Now, under a 3-year extension for its duty paid business and a newly awarded 12-year contract for duty free, Hudson will expand its footprint in BOS even further – introducing a locally-inspired, globally-relevant concessions portfolio consisting of eight new duty paid and eight duty free stores in 2023 and 2024.
Terminals A, B, and C will have a duty free store where both domestic and international travelers can shop.
Terminal E, which is only for international travelers, will offer five distinctive duty free shops including an immersive, 11,000-square-foot walk-through store.
In the B/C Connector, Hudson will introduce a combination Hudson and Dunkin’ concept, and in Terminal E, Hudson will open a hybrid Hudson and F&B marketplace.

Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases

Retrieved on:

Thursday, April 27, 2023

Therini Bio , Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the close of a $36M Series A financing round.

Key Points:

Therini Bio , Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the close of a $36M Series A financing round.
The Series A funding brings the total amount raised since inception to $62M.
The new funding will enable Therini Bio to advance its pipeline of fibrin-targeting therapies and advance its lead antibody THN391, that binds the inflammation-driving component of fibrin that is known to activate immune responses in neurodegenerative and ophthalmologic diseases.
“This funding will enable us to accelerate the development of our lead antibody program targeting inflammatory fibrin in neurodegenerative and retinal diseases.

What's Next Venture Summit Marks 20th Year as Thought Leaders Chart the Future of the Longevity Economy

Retrieved on:

Wednesday, April 19, 2023

LAFAYETTE, Calif., April 19, 2023 /PRNewswire/ -- Mary Furlong & Associates (MFA), producer of the longest running conference in the longevity economy, announced its 20th annual What's Next Longevity Venture Summit on June 14–15. With the theme The 2030 Horizon: Charting a Course for Longevity Investors and Entrepreneurs, the conference will bring together thought leaders, including active investors, entrepreneurs, incubators, nonprofits, government agencies and large companies focused on the $8.3 trillion longevity economy for keynote speeches, incisive panel discussions and two business competitions.

Key Points:

"We are proud to bring this industry-leading summit to the longevity market for the 20th year," said Mary Furlong, founder and president of MFA.
This platform for connecting the longevity ecosystem is critical in creating success in challenging environments like those facing entrepreneurs today."
As part of the 20th anniversary, Furlong asked 20 longevity thought leaders about their strategies 20 years ago, the biggest changes and their visions for the future.
The What's Next Longevity Venture Summit will take place at the Claremont Club & Spa, Berkeley, California on June 14-15.

KARTELL AND ILLYCAFFÈ: THE RECOVERY AND INNOVATION PROJECT THAT COMBINES DESIGN, TECHNOLOGY AND CIRCULAR ECONOMY CONTINUES

Retrieved on:

Monday, April 17, 2023

Antonio Citterio, Partnership, Kartell, Via Monte Napoleone, NIA, Recycling, Element, Marketing, Capsule, Beauty, Sierra Leone, Nature, Illy, Investment, ELA, Coffee, Renewable energy

The novelty of this year is the structure of the seat, made with the recycling system of Iperespresso capsules, in two color variants.

Key Points:

The novelty of this year is the structure of the seat, made with the recycling system of Iperespresso capsules, in two color variants.
In some islands of vegetation, green plexiglass volumes containing coffee capsules will be combined to emphasize the production process of the chair.
A way, also scenic, to emphasize how two excellences of Made in Italy contribute to the sustainability of the planet through the strengthening of circular economy production models.
On the occasion of the Salone del Mobile, the restaurant space will be furnished with Re-Chair and Eleganza chairs.

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Retrieved on:

Thursday, March 30, 2023

Drug development, EIP, Diffusion Pharmaceuticals, NIA, DSM-IV codes, DLB, CNS, Bangladesh Technical Education Board, Dementia, National Institute on Aging, International Conference on Emerging Infectious Diseases, MD, Patient, Lewy body, Diffusion, Conference, Pharmaceutical industry

BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (Diffusion or Diffusion Pharmaceuticals) (NASDAQ: DFFN), today announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies (DLB).

Key Points:

“With this proposed merger, we are creating a leading company focused on developing treatments for neurodegenerative diseases, beginning first with neflamapimod for the treatment of dementia with Lewy bodies, the second most common type of dementia after Alzheimer’s disease, and for which there are currently no approved treatments,” said John Alam, MD, Chief Executive Officer of EIP Pharma.
From this, EIP Pharma’s clinical programs, management team and corporate strategy stood out amongst the many bids we received,” said Robert J. Cobuzzi, Jr., Ph.D., Chief Executive Officer of Diffusion Pharmaceuticals.
“We believe this proposed merger is opportunistic and exciting for our shareholders, as EIP has built a robust pipeline of highly needed CNS therapeutic candidates, and we are highly confident in the capabilities of John and his team to support the leadership of the combined company.
The NIA grant funds will be disbursed over the course of the study as costs are incurred.

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

Retrieved on:

Thursday, March 23, 2023

SEQUEL, Education, Neurodegenerative disease, NIA, Geographic atrophy, Cognition, Research, CNS, Public expenditure, US, ATM, Patient, Therapy, IND, SHINE, Disease, Pharmaceutical industry, Cryptocurrency

ET to discuss results

Key Points:

ET to discuss results
PURCHASE, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
“We believe the momentum we built in 2022 positions us for further success with our clinical and operational agenda in 2023,” said Lisa Ricciardi, President and CEO of Cognition Therapeutics.
“In the fourth quarter of 2022, we saw improvement in all key aspects of our business.
Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

AECOM awarded project management consultancy services contract for Saudi Arabia’s NEOM International Airport

Retrieved on:

Wednesday, March 22, 2023

Commercial Building & Real Estate, Construction & Property, Consulting, Air, Engineering, Transport, Professional Services, Manufacturing, Architecture, NIA, ORAT, Travel, PMC, NEOM, NYSE, ACM, AECOM

AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, announced today that it has been awarded a multi-year contract to provide project management consultancy (PMC) services for NEOM International Airport (NIA), in the northwestern region of Saudi Arabia.

Key Points:

AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, announced today that it has been awarded a multi-year contract to provide project management consultancy (PMC) services for NEOM International Airport (NIA), in the northwestern region of Saudi Arabia.
AECOM’s scope will include project management for masterplanning, design and construction services, through to testing, commissioning, operational readiness, activation and transition (ORAT).
“We are very pleased to be part of this innovative NEOM project, which is set to transform travel between NEOM and the world,” said Lara Poloni, AECOM’s president.
“This contract is a testament to our leadership position in the region and to our continuous commitment to NEOM and the goals of Saudi Arabia’s Vision 2030.”

Sonde Health and MassGen Selected for MassAITC Pilot Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment

Retrieved on:

Monday, February 27, 2023

Digital technologies, and digital biomarkers in particular, have great potential to support this shift,” said David Liu, CEO of Sonde Health.

Key Points:

Digital technologies, and digital biomarkers in particular, have great potential to support this shift,” said David Liu, CEO of Sonde Health.
Participants will be ages 55 and above and represent a range of cognitive function from normal cognition through subjective cognitive decline, mild cognitive impairment (MCI), and mild dementia.
The longitudinal study will examine the potential for Sonde’s vocal biomarker platform to monitor and detect changes in cognitive function for individuals at home.
It will serve as an important reference data set to further test and validate vocal biomarkers relevant to the detection or monitoring of cognitive impairment.

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

Retrieved on:

Monday, February 27, 2023

Digital technologies, and digital biomarkers in particular, have great potential to support this shift,” said David Liu, CEO of Sonde Health.

Key Points:

Digital technologies, and digital biomarkers in particular, have great potential to support this shift,” said David Liu, CEO of Sonde Health.
Participants will be ages 55 and above and represent a range of cognitive function from normal cognition through subjective cognitive decline, mild cognitive impairment (MCI), and mild dementia.
The longitudinal study will examine the potential of Sonde’s vocal biomarker platform to monitor and detect changes in cognitive function for individuals at home.
Digital technologies, and digital biomarkers in particular, have great potential to support this shift,” said David Liu, CEO of Sonde Health.